Today, we will be studying why Horizon Therapeutics (HZNP) is an attractive investment for 2020.
Company overview
Today, Horizon Therapeutics stands at the cusp of a major transformation. Once known mainly for its primary care drugs, the company has emerged as a leading rare disease biopharmaceutical company. The company currently markets approximately 10 drugs, of which 6 are for rare and immunological conditions. Krystexxa, Ravicti, and Procysbi are the company's major revenue drivers. Horizon Therapeutics is focused on maximizing the value of Krystexxa. Besides, the company is also strengthening its rare disease pipeline